The QUIVAX 17.4 vaccine (also called QUIVAX-UAQ), developed by the Autonomous University of Queretaro (UAQ) is ready to advance to the human testing phase. But, according to information from UAQ educational authorities, the only drawback in the beginning of the tests is the budget, since 20 million pesos are required to continue with the next stage.

In an interview, Teresa Garcia Gasca, doctor and dean of the UAQ, discussed the composition of this new anti-COVID formula that has shown successful results in animal tests, registering a high level of efficiency against the various coronavirus mutations discovered.

"The vaccine protein is composed of six small peptides that are taken from the specula mold (...) Only one has a small amino acid change. So that makes us think, we hypothesize, that our vaccine could protect against other variants", stated Dr. Garcia Gasca.

Even though, unlike other countries, resources in Mexico are limited, the Queretaro dose is not the only one made in the country, since the Biomedical Research Institute (IIBm) belonging to the National Autonomous University of Mexico (UNAM) and the Michoacan University of San Nicolas de Hidalgo continue to advance in their studies to develop a vaccine against the SARS Cov-2 virus.

Once the testing phase is successfully concluded, the administration of this dose would begin in the summer of 2022. It is worth mentioning that to date, the country has accumulated more than 2.1 million cases of COVID-19 and 193 thousand deaths caused by the disease. The vaccines applied in Mexican territory amount to 4 million 5 thousand 131 doses, distributed among medical and educational personnel and adults over 60 years of age.

RELATED VIDEO: 5 million CanSino vaccines arrive in Mexico